世界の細胞分析市場2023-2031:エンドユーザー別(バイオテクノロジー・製薬企業、学術、化粧品産業、受託研究機関、受託開発・製造機関)

【英語タイトル】Cell Analysis Market (End-user: Biotechnology & Pharmaceutical Companies, Academia, Cosmetic Industry, Contract Research Organizations, and Contract Development & Manufacturing Organizations) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが出版した調査資料(TMR23DCB014)・商品コード:TMR23DCB014
・発行会社(調査会社):Transparency Market Research
・発行日:2023年8月
・ページ数:166
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,795 ⇒換算¥880,840見積依頼/購入/質問フォーム
Multi User(5名様閲覧)USD8,795 ⇒換算¥1,336,840見積依頼/購入/質問フォーム
Corporate License(法人閲覧)USD11,795 ⇒換算¥1,792,840見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

細胞分析市場 - レポートの範囲TMRの調査レポート「世界の細胞分析市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界の細胞分析市場の収益を提供しています。また、2023年から2031年までの世界の細胞分析市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、細胞分析市場を理解しました。

二次調査には、インターネットソース、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストはトップダウンアプローチとボトムアップアプローチを組み合わせて、世界の細胞分析市場の様々な属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは世界の細胞分析市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界の細胞分析市場への参入に関心のある企業にとっても貴重なツールとなります。

本レポートでは、世界の細胞分析市場の競争状況について掘り下げています。世界の細胞分析市場で事業を展開する主要プレイヤーを特定し、各プレイヤーを様々な属性でプロファイルしています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の細胞分析市場におけるプレイヤーの属性です。

世界の細胞分析市場レポートで回答された主な質問
- 予測期間中の全地域における細胞分析の売上高/収益は?
- 世界の細胞分析市場におけるビジネスチャンスは?
- 市場の主な促進要因、阻害要因、機会、脅威は?
- 予測期間中に最も速いCAGRで拡大する地域市場は?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは?
- 世界市場で事業を展開する各企業の市場ポジションは?

細胞分析市場 - 調査目的と調査アプローチ
世界の細胞分析市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。

本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフと表を適切に配置した網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化することで、読者に視覚的に訴えかけます。また、主要セグメントの過去と予測期間末の市場シェアの比較も可能です。

本レポートでは、世界の細胞分析市場を製品、エンドユーザー、地域の観点から分析。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界細胞分析市場への投資について十分な情報に基づいたビジネス上の意思決定を行うことができます。

1. 序論
2. 仮定・調査方法
3. 市場概要
4. 世界の細胞分析市場分析・予測:エンドユーザー別
5. 世界のバイオテクノロジー・製薬企業における細胞分析市場分析・予測:治療領域別
6. 世界のバイオテクノロジー・製薬企業における細胞分析市場分析・予測:技術別
7. 世界のバイオテクノロジー・製薬企業における細胞分析市場分析・予測:作業場所別
8. 世界のバイオテクノロジー・製薬企業における細胞分析市場分析・予測:国/地域別
9. アメリカの細胞分析市場分析・予測
10. ヨーロッパの細胞分析市場分析・予測
11. 中国の細胞分析市場分析・予測
12. その他地域の細胞分析市場分析・予測

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Preface
    1.1. Market Definition and Scope
    1.2. Key Research Objectives
2. Assumptions and Research Methodology
3. Market Overview
    3.1. Overview
    3.2. Market Dynamics
        3.2.1. Drivers
        3.2.2. Restraints
        3.2.3. Opportunities
    3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area
        3.3.1. Top 15 Origins of Pipeline Drugs
        3.3.2. Biological versus non-biological drugs as a % of pipeline
        3.3.3. Ongoing rise of gene and cell therapy
4. Global Cell Analysis Market Analysis and Forecast, by End-user
    4.1. Introduction & Definition
    4.2. Key Findings/Developments
    4.3. Market Value Forecast, by End-user, 2017-2031
        4.3.1. Biotechnology & Pharmaceutical Companies
        4.3.2. Academia
        4.3.3. Cosmetic Industry
        4.3.4. Contract Research Organizations
        4.3.5. Contract Development and Manufacturing Organizations
5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area
    5.1. Introduction & Definition
    5.2. Key Findings/Developments
    5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
        5.3.1. Oncology & Immune-oncology
            5.3.1.1. Small Molecules
            5.3.1.2. Protein-based Therapeutics
            5.3.1.3. Cell Therapy
            5.3.1.4. Nucleic Acid-based Drugs
        5.3.2. Cardiovascular & Metabolic Diseases
            5.3.2.1. Small Molecules
            5.3.2.2. Protein-based Therapeutics
            5.3.2.3. Cell Therapy
            5.3.2.4. Nucleic Acid-based Drugs
        5.3.3. Immunology
            5.3.3.1. Small Molecules
            5.3.3.2. Protein-based Therapeutics
            5.3.3.3. Cell Therapy
            5.3.3.4. Nucleic Acid-based Drugs
        5.3.4. Rare Diseases
            5.3.4.1. Small Molecules
            5.3.4.2. Protein-based Therapeutics
            5.3.4.3. Cell Therapy
            5.3.4.4. Nucleic Acid-based Drugs
        5.3.5. Neurological Diseases
            5.3.5.1. Small Molecules
            5.3.5.2. Protein-based Therapeutics
            5.3.5.3. Cell Therapy
            5.3.5.4. Nucleic Acid-based Drugs
        5.3.6. Others
            5.3.6.1. Small Molecules
            5.3.6.2. Protein-based Therapeutics
            5.3.6.3. Cell Therapy
            5.3.6.4. Nucleic Acid-based Drugs
6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Technology, 2017-2031
        6.3.1. Flow Cytometry
        6.3.2. Image-based Cytometry
        6.3.3. Biochemical Assays
        6.3.4. Mass Spectrometry
7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Workplace, 2017-2031
        7.3.1. Target Identification
        7.3.2. Hit Generation & Lead Identification
        7.3.3. Lead Optimization
        7.3.4. In Vitro Preclinical Studies
        7.3.5. In Vivo Preclinical Studies
        7.3.6. Clinical Studies
8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Country/Region, 2017-2031
        8.2.1. U.S.
        8.2.2. Europe
        8.2.3. China
        8.2.4. Rest of the World
9. U.S. Cell Analysis Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by End-user, 2017-2031
        9.2.1. Biotechnology & Pharmaceutical Companies
        9.2.2. Academia
        9.2.3. Cosmetic Industry
        9.2.4. Contract Research Organizations
        9.2.5. Contract Development and Manufacturing Organizations
    9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        9.3.1. Oncology & Immune-oncology
            9.3.1.1. Small Molecules
            9.3.1.2. Protein-based Therapeutics
            9.3.1.3. Cell Therapy
            9.3.1.4. Nucleic Acid-based Drugs
        9.3.2. Cardiovascular & Metabolic Diseases
            9.3.2.1. Small Molecules
            9.3.2.2. Protein-based Therapeutics
            9.3.2.3. Cell Therapy
            9.3.2.4. Nucleic Acid-based Drugs
        9.3.3. Immunology
            9.3.3.1. Small Molecules
            9.3.3.2. Protein-based Therapeutics
            9.3.3.3. Cell Therapy
            9.3.3.4. Nucleic Acid-based Drugs
        9.3.4. Rare Diseases
            9.3.4.1. Small Molecules
            9.3.4.2. Protein-based Therapeutics
            9.3.4.3. Cell Therapy
            9.3.4.4. Nucleic Acid-based Drugs
        9.3.5. Neurological Diseases
            9.3.5.1. Small Molecules
            9.3.5.2. Protein-based Therapeutics
            9.3.5.3. Cell Therapy
            9.3.5.4. Nucleic Acid-based Drugs
        9.3.6. Others
            9.3.6.1. Small Molecules
            9.3.6.2. Protein-based Therapeutics
            9.3.6.3. Cell Therapy
            9.3.6.4. Nucleic Acid-based Drugs
    9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
        9.4.1. Flow Cytometry
        9.4.2. Image-based Cytometry
        9.4.3. Biochemical Assays
        9.4.4. Mass Spectrometry
    9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        9.5.1. Target Identification
        9.5.2. Hit Generation & Lead Identification
        9.5.3. Lead Optimization
        9.5.4. In Vitro Preclinical Studies
        9.5.5. In Vivo Preclinical Studies
        9.5.6. Clinical Studies
10. Europe Cell Analysis Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by End-user, 2017-2031
        10.2.1. Biotechnology & Pharmaceutical Companies
        10.2.2. Academia
        10.2.3. Cosmetic Industry
        10.2.4. Contract Research Organizations
        10.2.5. Contract Development and Manufacturing Organizations
    10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        10.3.1. Oncology & Immune-oncology
            10.3.1.1. Small Molecules
            10.3.1.2. Protein-based Therapeutics
            10.3.1.3. Cell Therapy
            10.3.1.4. Nucleic Acid-based Drugs
        10.3.2. Cardiovascular & Metabolic Diseases
            10.3.2.1. Small Molecules
            10.3.2.2. Protein-based Therapeutics
            10.3.2.3. Cell Therapy
            10.3.2.4. Nucleic Acid-based Drugs
        10.3.3. Immunology
            10.3.3.1. Small Molecules
            10.3.3.2. Protein-based Therapeutics
            10.3.3.3. Cell Therapy
            10.3.3.4. Nucleic Acid-based Drugs
        10.3.4. Rare Diseases
            10.3.4.1. Small Molecules
            10.3.4.2. Protein-based Therapeutics
            10.3.4.3. Cell Therapy
            10.3.4.4. Nucleic Acid-based Drugs
        10.3.5. Neurological Diseases
            10.3.5.1. Small Molecules
            10.3.5.2. Protein-based Therapeutics
            10.3.5.3. Cell Therapy
            10.3.5.4. Nucleic Acid-based Drugs
        10.3.6. Others
            10.3.6.1. Small Molecules
            10.3.6.2. Protein-based Therapeutics
            10.3.6.3. Cell Therapy
            10.3.6.4. Nucleic Acid-based Drugs
    10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
        10.4.1. Flow Cytometry
        10.4.2. Image-based Cytometry
        10.4.3. Biochemical Assays
        10.4.4. Mass Spectrometry
    10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        10.5.1. Target Identification
        10.5.2. Hit Generation & Lead Identification
        10.5.3. Lead Optimization
        10.5.4. In Vitro Preclinical Studies
        10.5.5. In Vivo Preclinical Studies
        10.5.6. Clinical Studies
    10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
        10.6.1. EU5
        10.6.2. U.K.
        10.6.3. Switzerland
        10.6.4. Rest of Europe
11. China Cell Analysis Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by End-user, 2017-2031
        11.2.1. Biotechnology & Pharmaceutical Companies
        11.2.2. Academia
        11.2.3. Cosmetic Industry
        11.2.4. Contract Research Organizations
        11.2.5. Contract Development and Manufacturing Organizations
    11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        11.3.1. Oncology & Immune-oncology
            11.3.1.1. Small Molecules
            11.3.1.2. Protein-based Therapeutics
            11.3.1.3. Cell Therapy
            11.3.1.4. Nucleic Acid-based Drugs
        11.3.2. Cardiovascular & Metabolic Diseases
            11.3.2.1. Small Molecules
            11.3.2.2. Protein-based Therapeutics
            11.3.2.3. Cell Therapy
            11.3.2.4. Nucleic Acid-based Drugs
        11.3.3. Immunology
            11.3.3.1. Small Molecules
            11.3.3.2. Protein-based Therapeutics
            11.3.3.3. Cell Therapy
            11.3.3.4. Nucleic Acid-based Drugs
        11.3.4. Rare Diseases
            11.3.4.1. Small Molecules
            11.3.4.2. Protein-based Therapeutics
            11.3.4.3. Cell Therapy
            11.3.4.4. Nucleic Acid-based Drugs
        11.3.5. Neurological Diseases
            11.3.5.1. Small Molecules
            11.3.5.2. Protein-based Therapeutics
            11.3.5.3. Cell Therapy
            11.3.5.4. Nucleic Acid-based Drugs
        11.3.6. Others
            11.3.6.1. Small Molecules
            11.3.6.2. Protein-based Therapeutics
            11.3.6.3. Cell Therapy
            11.3.6.4. Nucleic Acid-based Drugs
    11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
        11.4.1. Flow Cytometry
        11.4.2. Image-based Cytometry
        11.4.3. Biochemical Assays
        11.4.4. Mass Spectrometry
    11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        11.5.1. Target Identification
        11.5.2. Hit Generation & Lead Identification
        11.5.3. Lead Optimization
        11.5.4. In Vitro Preclinical Studies
        11.5.5. In Vivo Preclinical Studies
        11.5.6. Clinical Studies
12. Rest of the World Cell Analysis Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by End-user, 2017-2031
        12.2.1. Biotechnology & Pharmaceutical Companies
        12.2.2. Academia
        12.2.3. Cosmetic Industry
        12.2.4. Contract Research Organizations
        12.2.5. Contract Development and Manufacturing Organizations
    12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
        12.3.1. Oncology & Immune-oncology
            12.3.1.1. Small Molecules
            12.3.1.2. Protein-based Therapeutics
            12.3.1.3. Cell Therapy
            12.3.1.4. Nucleic Acid-based Drugs
        12.3.2. Cardiovascular & Metabolic Diseases
            12.3.2.1. Small Molecules
            12.3.2.2. Protein-based Therapeutics
            12.3.2.3. Cell Therapy
            12.3.2.4. Nucleic Acid-based Drugs
        12.3.3. Immunology
            12.3.3.1. Small Molecules
            12.3.3.2. Protein-based Therapeutics
            12.3.3.3. Cell Therapy
            12.3.3.4. Nucleic Acid-based Drugs
        12.3.4. Rare Diseases
            12.3.4.1. Small Molecules
            12.3.4.2. Protein-based Therapeutics
            12.3.4.3. Cell Therapy
            12.3.4.4. Nucleic Acid-based Drugs
        12.3.5. Neurological Diseases
            12.3.5.1. Small Molecules
            12.3.5.2. Protein-based Therapeutics
            12.3.5.3. Cell Therapy
            12.3.5.4. Nucleic Acid-based Drugs
        12.3.6. Others
            12.3.6.1. Small Molecules
            12.3.6.2. Protein-based Therapeutics
            12.3.6.3. Cell Therapy
            12.3.6.4. Nucleic Acid-based Drugs
    12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
        12.4.1. Flow Cytometry
        12.4.2. Image-based Cytometry
        12.4.3. Biochemical Assays
        12.4.4. Mass Spectrometry
    12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
        12.5.1. Target Identification
        12.5.2. Hit Generation & Lead Identification
        12.5.3. Lead Optimization
        12.5.4. In Vitro Preclinical Studies
        12.5.5. In Vivo Preclinical Studies
        12.5.6. Clinical Studies

List of Tables

Table 01: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (1/4)

Table 02: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/4)

Table 03: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/3)

Table 04: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (4/4)

Table 05: Top 15 Origins of Pipeline Drugs

Table 06: Global Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 07: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

Table 08: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

Table 09: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

Table 10: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

Table 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

Table 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

Table 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

Table 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031

Table 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

Table 16: Global Cell Analysis Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 17: U.S. Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 18: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

Table 19: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

Table 20: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

Table 21: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

Table 22: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

Table 23: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

Table 24: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

Table 25: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031

Table 26: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

Table 27: Europe Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 28: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

Table 29: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

Table 30: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

Table 31: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

Table 32: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

Table 33: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

Table 34: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

Table 35: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031

Table 36: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

Table 37: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 38: China Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 39: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

Table 40: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

Table 41: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

Table 42: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

Table 43: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

Table 44: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

Table 45: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

Table 46: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031

Table 47: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

Table 48: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 49: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031

Table 50: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031

Table 51: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031

Table 52: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031

Table 53: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031

Table 54: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031

Table 55: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031

Table 56: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031

Table 57: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

★調査レポート[世界の細胞分析市場2023-2031:エンドユーザー別(バイオテクノロジー・製薬企業、学術、化粧品産業、受託研究機関、受託開発・製造機関)] (コード:TMR23DCB014)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の細胞分析市場2023-2031:エンドユーザー別(バイオテクノロジー・製薬企業、学術、化粧品産業、受託研究機関、受託開発・製造機関)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆